Compare Stocks: ALDX, IKT, AMRN, and ACB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.92	$3.68	$2.56 ▼ $6.66	$257.62M	0.63	730,000 shs	682,005 shs
ALDX Aldeyra Therapeutics	$1.17	$1.46	$1.07 ▼ $5.93	$70.59M	1.21	1.08 million shs	2.27 million shs
AMRN Amarin	$12.35	$13.87	$12.31 ▼ $20.90	$260.83M	0.76	52,492 shs	100,385 shs
IKT Inhibikase Therapeutics	$2.00	$2.33	$1.33 ▼ $2.61	$279.08M	0.89	556,944 shs	434,455 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	-4.39%	-0.76%	+44.65%	-30.62%
ALDX Aldeyra Therapeutics	0.00%	-2.90%	-20.95%	-48.68%	-79.62%
AMRN Amarin	0.00%	-6.44%	-9.39%	-21.49%	-34.45%
IKT Inhibikase Therapeutics	0.00%	-2.91%	-20.00%	+1.01%	+20.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.92	$3.68	$2.56 ▼ $6.66	$257.62M	0.63	730,000 shs	682,005 shs
ALDX Aldeyra Therapeutics	$1.17	$1.46	$1.07 ▼ $5.93	$70.59M	1.21	1.08 million shs	2.27 million shs
AMRN Amarin	$12.35	$13.87	$12.31 ▼ $20.90	$260.83M	0.76	52,492 shs	100,385 shs
IKT Inhibikase Therapeutics	$2.00	$2.33	$1.33 ▼ $2.61	$279.08M	0.89	556,944 shs	434,455 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	-4.39%	-0.76%	+44.65%	-30.62%
ALDX Aldeyra Therapeutics	0.00%	-2.90%	-20.95%	-48.68%	-79.62%
AMRN Amarin	0.00%	-6.44%	-9.39%	-21.49%	-34.45%
IKT Inhibikase Therapeutics	0.00%	-2.91%	-20.00%	+1.01%	+20.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	370.09% Upside
AMRN Amarin	1.33	Sell	$13.00	5.26% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	170.00% Upside

Current Analyst Ratings Breakdown

Latest ALDX, IKT, AMRN, and ACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/30/2026	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$2.00
9/29/2026	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$247.82M	1.04	$0.70 per share	5.58	$6.27 per share	0.63
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
AMRN Amarin	$213.65M	1.22	$0.36 per share	34.21	$22.07 per share	0.56
IKT Inhibikase Therapeutics	$260K	1,073.38	N/A	N/A	$2.30 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	65.33	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A

Latest ALDX, IKT, AMRN, and ACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
AMRN Amarin	N/A	3.67	2.67
IKT Inhibikase Therapeutics	N/A	15.82	15.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
ALDX Aldeyra Therapeutics	59.71%
AMRN Amarin	22.25%
IKT Inhibikase Therapeutics	3.81%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
ALDX Aldeyra Therapeutics	11.80%
AMRN Amarin	4.21%
IKT Inhibikase Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	65.72 million	65.72 million	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A

ALDX, IKT, AMRN, and ACB Headlines

Recent News About These Companies

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

3 hours ago | biospace.comB

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 4:01 PM | globenewswire.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Now Rated "Buy" by Wall Street Analysts

September 28, 2026 | americanbankingnews.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of "Buy" from Analysts

September 28, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Nuvation Bio (NUVB)

September 18, 2026 | theglobeandmail.com

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

August 11, 2026 | globenewswire.com

FDA grants orphan drug designation to IKT-001 for PAH

July 30, 2026 | healio.comH

FDA grants orphan drug status to experimental PAH treatment

July 27, 2026 | pulmonaryhypertensionnews.comP

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

July 23, 2026 | globenewswire.com

Inhibikase sells $50M of common stock to RA Capital

July 14, 2026 | msn.com

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

July 14, 2026 | globenewswire.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

June 29, 2026 | theglobeandmail.com

LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

May 17, 2026 | theglobeandmail.com

Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors

May 14, 2026 | tipranks.com

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

May 12, 2026 | globenewswire.com

Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension

May 12, 2026 | tipranks.com

Inhibikase enrolls first patient in phase 3 PAH trial

April 14, 2026 | msn.com

Inhibikase grants stock options to five new employees

April 8, 2026 | msn.com

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

April 7, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)

April 6, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, AMRN, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

$3.92 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.90 -0.02 (-0.64%)

As of 07:19 AM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aldeyra Therapeutics NASDAQ:ALDX

$1.17 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.26 +0.09 (+7.61%)

As of 07:05 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Amarin NASDAQ:AMRN

$12.35 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$12.34 0.00 (-0.04%)

As of 07:00 AM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inhibikase Therapeutics NASDAQ:IKT

$2.00 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 10/2/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, IKT, AMRN, and ACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, IKT, AMRN, and ACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, IKT, AMRN, and ACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, AMRN, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

Aldeyra Therapeutics NASDAQ:ALDX

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, IKT, AMRN, and ACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, IKT, AMRN, and ACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, IKT, AMRN, and ACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, AMRN, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

Aldeyra Therapeutics NASDAQ:ALDX

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools